All Biomarkers

    GFAP (Glial Fibrillary Acidic Protein)

    Neurological
    Astroglial
    pg/mL

    Glial fibrillary acidic protein (GFAP) is released when astrocytes, the brain's support cells, become activated by injury or disease. A preventive practice tracks this emerging blood marker because elevations accompany Alzheimer's disease, brain injury, and neuroinflammation.

    What It Measures

    Glial fibrillary acidic protein (GFAP) is the main intermediate-filament protein of astrocytes, the brain's support cells. Plasma GFAP rises when astrocytes become reactive ("astrogliosis"), notably in response to amyloid-beta pathology, and is used as a blood marker of amyloid-associated astrocyte activation and neuroinflammation.

    Optimal vs. Lab Range

    Longevity Optimal
    At or below the age-adjusted reference interval for the reporting assay.

    Target range for optimal health and longevity based on research.

    Standard Lab
    Age-dependent and assay-specific; no universal reference range.

    Population-based reference range from standard labs.

    Why It Matters

    Plasma GFAP is an early, amyloid-associated marker of Alzheimer's-type pathology: it increases in the pre-symptomatic (amyloid-positive) stage and tracks amyloid-beta more closely than tau. In prospective cohorts, higher plasma GFAP predicts progression from mild cognitive impairment to Alzheimer's dementia and is associated with cognitive decline in older adults, and recent work reports plasma GFAP can outperform CSF GFAP for detecting amyloid pathology. Combined with p-tau217 and NfL, GFAP strengthens a blood-based panel for Alzheimer's risk stratification. Because GFAP reflects astrocyte reactivity to amyloid rather than being disease-specific, it is interpreted as part of a panel and in clinical context, not as a stand-alone test.

    When Low

    Low/age-appropriate GFAP: little evidence of amyloid-associated astrocyte reactivity at the time of testing.

    When Optimal

    At or below the age-adjusted reference: reassuring; best interpreted alongside p-tau and NfL.

    When High

    Above the age-adjusted reference: suggests amyloid-associated astrogliosis/neuroinflammation; correlate clinically and consider confirmatory AD biomarker testing and neurology referral.

    How to Optimize

    GFAP reflects amyloid-linked astrocyte reactivity and neuroinflammation, so efforts focus on the shared, modifiable drivers of brain aging: a Mediterranean/MIND dietary pattern, regular aerobic and resistance exercise, good sleep, control of blood pressure, glucose and ApoB, and avoiding smoking. Where GFAP and companion markers indicate likely amyloid pathology, management is guided by neurology. This content is educational and not a substitute for medical advice.

    Key Interventions & Linked Compounds

    Strong (7/10)

    Key Interventions

    MIND/Mediterranean diet
    aerobic + resistance exercise
    sleep
    BP/glucose/ApoB control
    smoking cessation
    neurology-guided management where amyloid pathology is indicated.

    Linked Compounds & Supplements

    Curcumin
    omega-3.

    Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

    Ordering Notes

    Specimen

    High-sensitivity plasma assay (SIMOA)

    Patient prep

    No fasting required. Maintain usual diet and medications unless advised.

    Recommended cadence

    As clinically indicated or periodically as part of a brain-health panel; compare on the same assay

    Reporting unit

    pg/mL

    Pre-analytic notes

    Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

    Available panels

    High-sensitivity plasma assay (SIMOA)
    Plasma immunoassay

    Recommended Follow-Up Actions

    1. 1

      Confirm the result is reliable

      Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift GFAP (Glial Fibrillary Acidic Protein).

    2. 2

      Compare against optimal, not just lab range

      Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.

    3. 3

      Pair with related markers

      Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.

    4. 4

      Discuss interventions with a clinician

      Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.

    5. 5

      Re-test on a defined cadence

      If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.

    Testing Information

    Recommended Frequency

    As clinically indicated or periodically as part of a brain-health panel; compare on the same assay

    Fasting Requirement

    No fasting required

    Available Test Types

    High-sensitivity plasma assay (SIMOA)
    Plasma immunoassay
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation